Molecular pathways and targets in prostate cancer

Emma Shtivelman, Tomasz M. Beer, Christopher P Evans

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The heterogeneity of prostate cancers is evident at earlier stages, and has led to rigorous efforts to stratify the localized prostate cancers, so that progression to advanced stages could be predicted based upon salient features of the early disease. The deregulated androgen receptor signaling is undeniably most important in the progression of the majority of prostate tumors. It is perhaps because of the primacy of the androgen receptor governed transcriptional program in prostate epithelium cells that once this program is corrupted, the consequences of the ensuing changes in activity are pleotropic and could contribute to malignancy in multiple ways. Following localized surgical and radiation therapies, 20-40% of patients will relapse and progress, and will be treated with androgen deprivation therapies. The successful development of the new agents that inhibit androgen signaling has changed the progression free survival in hormone resistant disease, but this has not changed the almost ubiquitous development of truly resistant phenotypes in advanced prostate cancer. This review summarizes the current understanding of the molecular pathways involved in localized and metastatic prostate cancer, with an emphasis on the clinical implications of the new knowledge.

Original languageEnglish (US)
Pages (from-to)7217-7259
Number of pages43
JournalOncotarget
Volume5
Issue number17
StatePublished - 2014

Fingerprint

Prostatic Neoplasms
Androgen Receptors
Androgens
Prostate
Disease-Free Survival
Neoplasms
Radiotherapy
Epithelium
Hormones
Phenotype
Recurrence
Therapeutics

Keywords

  • CRPC
  • Localized prostate cance
  • Molecular targets
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Shtivelman, E., Beer, T. M., & Evans, C. P. (2014). Molecular pathways and targets in prostate cancer. Oncotarget, 5(17), 7217-7259.

Molecular pathways and targets in prostate cancer. / Shtivelman, Emma; Beer, Tomasz M.; Evans, Christopher P.

In: Oncotarget, Vol. 5, No. 17, 2014, p. 7217-7259.

Research output: Contribution to journalArticle

Shtivelman, E, Beer, TM & Evans, CP 2014, 'Molecular pathways and targets in prostate cancer', Oncotarget, vol. 5, no. 17, pp. 7217-7259.
Shtivelman E, Beer TM, Evans CP. Molecular pathways and targets in prostate cancer. Oncotarget. 2014;5(17):7217-7259.
Shtivelman, Emma ; Beer, Tomasz M. ; Evans, Christopher P. / Molecular pathways and targets in prostate cancer. In: Oncotarget. 2014 ; Vol. 5, No. 17. pp. 7217-7259.
@article{706e4f5326ed4d29a55ffb085cd57651,
title = "Molecular pathways and targets in prostate cancer",
abstract = "Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The heterogeneity of prostate cancers is evident at earlier stages, and has led to rigorous efforts to stratify the localized prostate cancers, so that progression to advanced stages could be predicted based upon salient features of the early disease. The deregulated androgen receptor signaling is undeniably most important in the progression of the majority of prostate tumors. It is perhaps because of the primacy of the androgen receptor governed transcriptional program in prostate epithelium cells that once this program is corrupted, the consequences of the ensuing changes in activity are pleotropic and could contribute to malignancy in multiple ways. Following localized surgical and radiation therapies, 20-40{\%} of patients will relapse and progress, and will be treated with androgen deprivation therapies. The successful development of the new agents that inhibit androgen signaling has changed the progression free survival in hormone resistant disease, but this has not changed the almost ubiquitous development of truly resistant phenotypes in advanced prostate cancer. This review summarizes the current understanding of the molecular pathways involved in localized and metastatic prostate cancer, with an emphasis on the clinical implications of the new knowledge.",
keywords = "CRPC, Localized prostate cance, Molecular targets, Prostate cancer",
author = "Emma Shtivelman and Beer, {Tomasz M.} and Evans, {Christopher P}",
year = "2014",
language = "English (US)",
volume = "5",
pages = "7217--7259",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "17",

}

TY - JOUR

T1 - Molecular pathways and targets in prostate cancer

AU - Shtivelman, Emma

AU - Beer, Tomasz M.

AU - Evans, Christopher P

PY - 2014

Y1 - 2014

N2 - Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The heterogeneity of prostate cancers is evident at earlier stages, and has led to rigorous efforts to stratify the localized prostate cancers, so that progression to advanced stages could be predicted based upon salient features of the early disease. The deregulated androgen receptor signaling is undeniably most important in the progression of the majority of prostate tumors. It is perhaps because of the primacy of the androgen receptor governed transcriptional program in prostate epithelium cells that once this program is corrupted, the consequences of the ensuing changes in activity are pleotropic and could contribute to malignancy in multiple ways. Following localized surgical and radiation therapies, 20-40% of patients will relapse and progress, and will be treated with androgen deprivation therapies. The successful development of the new agents that inhibit androgen signaling has changed the progression free survival in hormone resistant disease, but this has not changed the almost ubiquitous development of truly resistant phenotypes in advanced prostate cancer. This review summarizes the current understanding of the molecular pathways involved in localized and metastatic prostate cancer, with an emphasis on the clinical implications of the new knowledge.

AB - Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The heterogeneity of prostate cancers is evident at earlier stages, and has led to rigorous efforts to stratify the localized prostate cancers, so that progression to advanced stages could be predicted based upon salient features of the early disease. The deregulated androgen receptor signaling is undeniably most important in the progression of the majority of prostate tumors. It is perhaps because of the primacy of the androgen receptor governed transcriptional program in prostate epithelium cells that once this program is corrupted, the consequences of the ensuing changes in activity are pleotropic and could contribute to malignancy in multiple ways. Following localized surgical and radiation therapies, 20-40% of patients will relapse and progress, and will be treated with androgen deprivation therapies. The successful development of the new agents that inhibit androgen signaling has changed the progression free survival in hormone resistant disease, but this has not changed the almost ubiquitous development of truly resistant phenotypes in advanced prostate cancer. This review summarizes the current understanding of the molecular pathways involved in localized and metastatic prostate cancer, with an emphasis on the clinical implications of the new knowledge.

KW - CRPC

KW - Localized prostate cance

KW - Molecular targets

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84907536832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907536832&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 7217

EP - 7259

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 17

ER -